Highly-Anticipated Regulation Changes In 2021 Could Revolutionize America’s CBD Sector

By Mark Sheridan



HempFusion Wellness – The one stock to ride in the Second Green Wave

The market for CBD products is evolving and growing enormously…

In the US alone, it’s estimated that sales will hit US$16.8 billion by 2025 from just US$4 billion at present.

Around the world the outlook is even better.

The European market is set to grow by 400% through 2023, while the Canadian space is expected to rise to C$2.4 billion in value within a few years.

What’s driving this momentum is a compelling investment theme.

With the Biden Administration and a democratic congress likely ushering in more liberal policies, there may be significant rule changes coming to the CBD market. The FDA may also update CBD rules that could be hugely transformative for the industry. All this may have ‘Big Pharma’ looking at potential M&A or investment opportunities in CBD to hedge their bets.

This may all be happening sooner than we think… Recently Jazz Pharmaceuticals announced that they would be acquiring GW Pharmaceuticals, a UK-based CBD company, for roughly $7 Billion. Who knows what could be next?

More and more studies are also finding that CBD – also known as cannabidiol – can help to support so many different aspects of the body and may have supportive and medical benefits.

As a result, acceptance of this key non-psychoactive substance, which is found in cannabis plants, is spiraling among consumers.

Just look at a recent poll from SingleCare.

It found that a third of American adults have already used CBD once or more to support areas like pain relief, stress, and sleep.

And when you consider that the younger generations are now more concerned than ever before with their wellness, the growth potential is enormous.

It’s no wonder companies are scrambling to capture a piece of this market.

Investors would be wise to keep a very close eye on how quickly this opportunity is developing.

See, nowadays, you can find thousands of companies putting “CBD” on labels to sell their products.

But the ugly truth is that the vast majority of these players are not compliant and may not even be safe to consume.

They are focused solely on developing products and making sales as quickly as possible.

As you’d expect, these players will be extremely exposed if the US Food and Drug Administration (“FDA”) were to crack down on the sector.

And unfortunately for them, it now looks like this is exactly what is about to happen.

A “blue wave” has swept over the US government – it isn’t just the president who sits on the left now, it’s the Congress and Senate as well.

The Democratic national agenda is expected to place a heavy emphasis on the legalization of cannabis and cannabis-derived products like CBD…

Many now expect monumental change in the American CBD market.

The impact would be twofold.

On the one hand, we could see a much, much wider pool of products on the market like CBD-infused foods, drinks, and dietary supplements.

On the other hand, the FDA is almost certain to tighten up its regulation of the sector, requiring compliance in areas like safety, quality and efficacy.

This is where HempFusion Wellness Inc (OTC:CBDHF | TSE:CBD.U | FWB:8OO) comes in.

See, this firm has invested millions of dollars in making its CBD products meet compliance and human safety standards both in the US and internationally.

So, if the FDA zones in on this sector and wipes out the vast majority of the more poorly prepared players…

HempFusion (OTC:CBDHF | TSE:CBD.U | FWB:8OO) could be positioned to capture a significant share of the CBD market as it hits terminal velocity.

It may be early investors who are the most richly-rewarded.


Five areas where HempFusion has a competitive edge today



HempFusion’s (OTC:CBDHF | TSE:CBD.U | FWB:8OO) range of CBD products is positioned to meet all of the FDA’s current compliance standards as well as those expected to come into play as the industry grows.

Not only is it one of very few CBD players that can legally make properly supported structure claims on its labels, but its offerings are include materials that have been evaluated as safe for human consumption and application.

It’s even one of ten companies taking part in ValidCare’s ground-breaking study into CBD and human safety, the results of which are eagerly anticipated by both the CPG and life sciences industries…



HempFusion (OTC:CBDHF | TSE:CBD.U | FWB:8OO) currently stocks 46 products in around 4,000 retail locations across 50 states, including Sprouts, Vitamin Shoppe and Fresh Thyme Market.

Alongside its OTC Drug Listed topicals like pain, eczema, and acne relief and Aging Beauty creams, their product range includes USDA Certified Organic CBD liquid hemp extract tinctures and CBD capsules for sleep, stress, and energy.

It’s not just traditional retail where HempFusion (OTC:CBDHF | TSE:CBD.U | FWB:8OO) is established, either. The company recently relaunched its e-commerce platform and is currently executing a multi-stage marketing plan to maximize its online presence.



HempFusion (OTC:CBDHF | TSE:CBD.U | FWB:8OO) plans to use its strong regulatory standards to enter new US sales channels where its peers could struggle to secure access.

There’s the Big Box Retail, where it recently became one of few CBD firms to meet the channel’s ultra-high-quality standards….

There’s the Doctor/Practitioner market, where it is negotiating supply agreements for a CBD channel expected to be worth US$2 billion annually by 2024…

And it is planning to enter the convenience market, too, where its products could be put in front of an immediately-addressable market of 27,842 stores.

Then there’s the rest of the world.

HempFusion (OTC:CBDHF | TSE:CBD.U | FWB:8OO) has carefully devised a “trojan horse” strategy in which it uses its range of non-CBD Probulin probiotics products to establish sales distribution channels with retailers in international markets.

When the rules around CBD change in these new spaces, the company could be ready to pounce with a full range of certified, innovative products.


HempFusion’s (OTC:CBDHF | TSE:CBD.U | FWB:8OO) management and executive team comprises some of the CBD sector’s most highly respected individuals.

For example, visionary founder Dr. Jason Mitchell, N.D. has already launched more than 300 dietary supplements and related products in the market…

Director Desmond Balakrishnan is a lawyer who has represented many of the cannabis industries biggest names, such as Aurora Cannabis…

And fellow director David Doherty was an initial financier and director of Green Organic Dutchman – one of the largest-ever Canadian cannabis IPOs.


On top of its compliance standards, market position, product range, and leadership team, HempFusion (OTC:CBDHF | TSE:CBD.U | FWB:8OO) has the money to potentially turn its plans into a reality.

As well as generating revenues from its existing CBD product sales, the firm was recently capitalized through its US$17 million IPO financing.

This bolstered an already strong balance sheet boasting no long-term debt and a cash balance of US13 million as of September 2020.

These factors combine to create a potentially huge opportunity for retail investors, as the CBD sector tightens and grows worldwide.

This is especially true with HempFusion (OTC:CBDHF | TSE:CBD.U | FWB:8OO) recently launched in the Canadian, US, and German markets. This highlights the firm to an army of investors hungry for innovative opportunities that give them exposure to the CBD space.

With such a strong commercial foundation in place, and one of the market’s leading product ranges, expect to see big things from HempFusion (OTC:CBDHF | TSE:CBD.U | FWB:8OO) over the coming years.




This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by HEMPFUSION WELLNESS INC. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred sixty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.


valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.


In this article:


Author: Mark Sheridan

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter